Zynex Inc ( (ZYXI) ) has released its Q3 earnings. Here is a breakdown of the information Zynex Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zynex, Inc. is a medical technology company that develops, manufactures, and sells non-invasive medical devices for pain management and rehabilitation, as well as monitoring systems for hospital use. In its third-quarter 2025 financial report, Zynex revealed significant financial challenges, including a substantial decline in revenue and a net loss, attributed to payment suspensions and operational setbacks. The company’s net revenue for the quarter was $13.4 million, a sharp decrease from $50 million in the same period the previous year, primarily due to issues with Tricare payments and changes in payer claim practices. Zynex reported a net loss of $42.9 million, exacerbated by a $30.7 million non-cash asset impairment charge. The company is actively exploring strategic alternatives to address its liquidity challenges, including potential capital raising and restructuring strategies, with the assistance of financial advisory firm Province, LLC. Looking ahead, Zynex’s management remains focused on navigating its current financial difficulties and exploring strategic options to stabilize and potentially grow the company in the future.